Literature DB >> 8103673

Deletions in the ligand for CD40 in X-linked immunoglobulin deficiency with normal or elevated IgM (HIGMX-1).

N Ramesh1, R Fuleihan, V Ramesh, S Lederman, M J Yellin, S Sharma, L Chess, F S Rosen, R S Geha.   

Abstract

Patients with X-linked Ig deficiency with normal or elevated IgM (HIGMX-1) fail to switch from IgM/IgD to other Ig isotypes. Interaction between the B cell antigen CD40 and the CD40 ligand expressed on activated T cells is critical for T cell driven isotype switching. We have reported that T lymphocytes from three unrelated male patients with HIGMX-1 failed to express CD40 ligand on their surface, but the mRNA for CD40 ligand was of an apparently normal size and level. Analysis of CD40 ligand cDNA from two of the patients revealed deletions that alter the reading frame. Patient 1 displayed two mutations: a C-->A transversion at nucleotide 590 and the deletion of an adjacent C nucleotide. The second patient had a 58 bp deletion from nucleotides 289-346. Furthermore, neither patient expressed a protein product detectable by the CD40L mAb, 5c8.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8103673     DOI: 10.1093/intimm/5.7.769

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  23 in total

1.  Non-functional immunoglobulin G transcripts in a case of hyper-immunoglobulin M syndrome similar to type 4.

Authors:  John M Darlow; Alex M Farrell; David I Stott
Journal:  Immunology       Date:  2004-02       Impact factor: 7.397

2.  Increased expression of CD40 ligand on systemic lupus erythematosus lymphocytes.

Authors:  M Koshy; D Berger; M K Crow
Journal:  J Clin Invest       Date:  1996-08-01       Impact factor: 14.808

3.  The role of polar interactions in the molecular recognition of CD40L with its receptor CD40.

Authors:  J Singh; E Garber; H Van Vlijmen; M Karpusas; Y M Hsu; Z Zheng; J H Naismith; D Thomas
Journal:  Protein Sci       Date:  1998-05       Impact factor: 6.725

4.  A novel CD40LG deletion causes the hyper-IgM syndrome with normal CD40L expression in a 6-month-old child.

Authors:  Gabriela López-Herrera; José Luis Maravillas-Montero; Alexander Vargas-Hernández; Laura Berrón-Ruíz; Emmanuel Ramírez-Sánchez; Marco Antonio Yamazaki-Nakashimada; Francisco Javier Espinosa-Rosales; Leopoldo Santos-Argumedo
Journal:  Immunol Res       Date:  2015-05       Impact factor: 2.829

5.  Defects of T-cell effector function and post-thymic maturation in X-linked hyper-IgM syndrome.

Authors:  A Jain; T P Atkinson; P E Lipsky; J E Slater; D L Nelson; W Strober
Journal:  J Clin Invest       Date:  1999-04       Impact factor: 14.808

6.  Classification of mutations in the human CD40 ligand, gp39, that are associated with X-linked hyper IgM syndrome.

Authors:  J Bajorath; K Seyama; S Nonoyama; H D Ochs; A Aruffo
Journal:  Protein Sci       Date:  1996-03       Impact factor: 6.725

Review 7.  Common variable immunodeficiency: clinical aspects and recent progress in identifying the immunological defect(s).

Authors:  M M Eibl; H M Wolf
Journal:  Folia Microbiol (Praha)       Date:  1995       Impact factor: 2.099

8.  Reduced pathology following infection with transgenic Leishmania major expressing murine CD40 ligand.

Authors:  Ann E Field; Sagie Wagage; Sean M Conrad; David M Mosser
Journal:  Infect Immun       Date:  2007-04-02       Impact factor: 3.441

9.  Clinical and molecular features of X-linked hyper IgM syndrome - An experience from North India.

Authors:  Amit Rawat; Babu Mathew; Vignesh Pandiarajan; Ankur Jindal; Madhubala Sharma; Deepti Suri; Anju Gupta; Shubham Goel; Adil Karim; Biman Saikia; Ranjana W Minz; Kohsuke Imai; Shigeaki Nonoyama; Osamu Ohara; Silvia Clara Giliani; Luigi D Notarangelo; Koon-Wing Chan; Yu-Lung Lau; Surjit Singh
Journal:  Clin Immunol       Date:  2018-07-25       Impact factor: 3.969

10.  Glucocorticoids upregulate CD40 ligand expression and induce CD40L-dependent immunoglobulin isotype switching.

Authors:  H H Jabara; S R Brodeur; R S Geha
Journal:  J Clin Invest       Date:  2001-02       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.